Protein expression changes in ovarian cancer during the transition from benign to malignant.
about
Mass spectrometry for translational proteomics: progress and clinical implicationsDIANA--algorithmic improvements for analysis of data-independent acquisition MS data.Proteomics of follicular fluid from women with polycystic ovary syndrome suggests molecular defects in follicular development.A cancer-related protein 14-3-3ζ is a potential tumor-associated antigen in immunodiagnosis of hepatocellular carcinoma.PeptideManager: a peptide selection tool for targeted proteomic studies involving mixed samples from different species.Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics.A quantitative proteomics-based signature of platinum sensitivity in ovarian cancer cell lines.Proteomic identification of fucosylated haptoglobin alpha isoforms in ascitic fluids and its localization in ovarian carcinoma tissues from Mexican patients.Proteomics in cancer biomarkers discovery: challenges and applications.Quantitative proteomic analysis of mitochondria from human ovarian cancer cells and their paclitaxel-resistant sublinesPotential tumor biomarkers identified in ovarian cyst fluid by quantitative proteomic analysis, iTRAQ.Proteomic analysis of breast tumors confirms the mRNA intrinsic molecular subtypes using different classifiers: a large-scale analysis of fresh frozen tissue samples.Investigating the clinical potential for 14-3-3 zeta protein to serve as a biomarker for epithelial ovarian cancer.Clinicopathologic significance of claudin-6, occludin, and matrix metalloproteinases -2 expression in ovarian carcinoma.LncRNAs expression profiling in normal ovary, benign ovarian cyst and malignant epithelial ovarian cancer.A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients.Phosphoproteomics of Primary Cells Reveals Druggable Kinase Signatures in Ovarian Cancer.Microarray analysis reveals differentially expressed lncRNAs in benign epithelial ovarian cysts and normal ovaries.Combined Mass Spectrometry Imaging and Top-down Microproteomics Reveals Evidence of a Hidden Proteome in Ovarian Cancer.Understanding Ovarian Cancer: iTRAQ-Based Proteomics for Biomarker DiscoveryMicroproteomics by liquid extraction surface analysis: Application to FFPE tissue to study the fimbria region of tubo-ovarian cancer
P2860
Q26995497-AE99EADE-5E93-4D09-AEF5-71B903BBA1E7Q30864255-210D7C16-0B5A-4431-9353-B39D738624CFQ33570233-5DFAF56B-714C-46E1-B318-32FF7366DF51Q33895863-7F3665E5-34DB-4AEF-A97B-FD0D84E409D8Q34117442-EE41459B-68E6-4A23-96C1-8B9B6B6489BDQ34333925-5797B8A9-9362-4D9C-8C59-A07C86E6C5ECQ35031170-4F729B02-A4CB-4520-8101-1D817AF5ABE9Q35104034-13FFC840-7154-46E1-A7BA-CFD61C0E786DQ35592114-AD50510A-BC35-4E79-808D-98B5411BABC5Q35649272-9A03D4D7-8165-487A-88D5-13225EEB6111Q36797835-0D27F58C-28C8-4561-9762-EFD18F776E3AQ37054767-F2440963-AAC7-409B-910B-9430C6E2D28CQ37329737-4E83E681-2AA6-4100-A011-8705376C784EQ37400120-1F008C8E-7CB7-4E86-B29E-A95E42D79CFEQ37492937-E3C30B26-AB6E-4627-9BC3-A5734D87C5C4Q37612098-C099CFE4-95D8-4BAC-A91E-A70C1DAA61A3Q37739177-F270ED2C-988E-4340-8F96-13BA25A59222Q38431931-BBBCE77A-C91B-4B33-849D-899DC137A503Q41040816-6ED89C84-54F5-43E3-A416-5A22D84F2A0FQ57173976-8F82B828-9C2A-47C9-A7B7-B879C37380F6Q58356277-5BF3C364-ABDD-458D-87A6-CC63CB4FE664
P2860
Protein expression changes in ovarian cancer during the transition from benign to malignant.
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Protein expression changes in ...... tion from benign to malignant.
@ast
Protein expression changes in ...... tion from benign to malignant.
@en
Protein expression changes in ...... tion from benign to malignant.
@nl
type
label
Protein expression changes in ...... tion from benign to malignant.
@ast
Protein expression changes in ...... tion from benign to malignant.
@en
Protein expression changes in ...... tion from benign to malignant.
@nl
prefLabel
Protein expression changes in ...... tion from benign to malignant.
@ast
Protein expression changes in ...... tion from benign to malignant.
@en
Protein expression changes in ...... tion from benign to malignant.
@nl
P2093
P50
P356
P1476
Protein expression changes in ...... tion from benign to malignant.
@en
P2093
Ayodele Alaiya
Karin M Hansson
Kjell Schedvins
Morten Krogh
Peter James
Reto Ossola
Sofia Waldemarson
P304
P356
10.1021/PR201258Q
P577
2012-04-17T00:00:00Z